TCT 920: Early US Commercial Experience With an Intra-Annular, Self-Expandable Valve in High-Risk Patients: 30-Day Results From the Navitor™ Post-Approval Study

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Medtronic; Edwards Lifesciences; Abbott